15th week of 2010 patent applcation highlights part 51 |
Patent application number | Title | Published |
20100093803 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF - The present application relates to novel substituted dipyridyldihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing. | 2010-04-15 |
20100093804 | NOVEL CRYSTALLINE FORM OF LANSOPRAZOLE - The present invention relates to a novel and stable crystalline polymorph of lansoprazole, a process for its preparation and to a pharmaceutical composition comprising it. Thus, for example, lansoprazole crude is dissolved in methanol at 20-30° C. followed by stirring and the solution is cooled to 0-10° C. The resulting solution is stirred for 1 hour to 1 hour 30 minutes at 0-10° C., the solid is filtered and then dried to give lansoprazole crystalline form III. | 2010-04-15 |
20100093805 | METHOD OF TREATING AMBLYOPIA - The present invention relates to a method of treating or alleviating the symptoms of amblyopia. It is based on the discovery that repeated administration of a specific drug, which is known to be clinically active to treat depression in humans, results in improved vision of the amblyopic eye. | 2010-04-15 |
20100093806 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING AMINOINDAZOLE AND AMINOBENZOFURAN ANALOGS - PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs. The compounds of the present invention are of Formulas I and II: | 2010-04-15 |
20100093807 | SUBSTITUTED 7-AZABICYCLO[2.2.1]HEPTYL DERIVATIVES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS - This invention provides 1-substituted-7-azabicyclo[2.2.1]heptyl derivatives, intermediates and methods for producing them, which are therapeutic agents useful for the prevention and treatment of central nervous system disorders and diseases mediated by a Nicotinic Acetylcholine Receptor such as Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, pain, nicotine addiction and dementia. | 2010-04-15 |
20100093808 | SALT AND POLYMORPH OF A DPP-IV INHIBITOR - The invention is concerned with (2S)-1-{[1,1-Dimethyl-3-(4-pyridin-3-yl-imidazol-1-yl)-propylamino]-acetyl}-pyrrolidine-2-carbonitrile fumarate and crystalline polymorphs of this compound. This compound and its polymorphic forms exhibits superior properties compared to the previously known compounds and can be used as medicament for the treatment of disorders which are associated with DPP-IV. | 2010-04-15 |
20100093809 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS - A compound having a structure | 2010-04-15 |
20100093810 | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis - The present invention provides methods for reducing Aβ deposition, Aβ neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine, also known as (−)-nilvadipine, to the animal or human, or by administering a non-racemic enantiomeric mixture of the dihydropyridine compound nilvadipine, to the animal or human. Further provided are methods for reducing the risk of Aβ deposition, Aβ neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering (−)-nilvadipine, or non-racemic mixture of nilvadipine enantiomers, after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter. | 2010-04-15 |
20100093811 | HIV PROTEASE INHIBITORS - Compounds of Formula I are disclosed: (I), wherein X | 2010-04-15 |
20100093812 | DESFERRITHIOCIN POLYETHER ANALOGUES - A relatively non-toxic desazadesferrithiocin analog having the formula (I): wherein: R | 2010-04-15 |
20100093813 | Salts 668 - A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD). | 2010-04-15 |
20100093814 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF - The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, | 2010-04-15 |
20100093815 | MICROBICIDAL COMPOSITIONS - The invention relates to synergistic mixtures of o-phenylphenol with other microbicidally active compounds, such as bronopol (2-bromo-2-nitro-1,3-propanedial), 2-methyl-2H-isothiazol-3-one, 1,2-dibromo-2,4-dicyanobutane. | 2010-04-15 |
20100093816 | SALT - The invention provides [2-(4-chloro-benzyloxy)-ethyl]-[2-((R)-cyclohexyl-hydroxy-phenyl-methyl)-oxazol-5-yl-methyl]-dimethyl-ammonium napadisylate, pharmaceutical compositions containing it, and its use in therapy. | 2010-04-15 |
20100093817 | Compounds - This invention relates to new 6,8-difluorochroman-3-yl-1,3-dihydroimidazole-2-thiones, their preparation, and their use as a medicament. | 2010-04-15 |
20100093818 | BENZIMIDAZOLE DERIVATIVES - The invention is concerned with novel benzimidazole derivatives of formula (I) | 2010-04-15 |
20100093819 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF - A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA | 2010-04-15 |
20100093820 | CRYSTALLINE PYRAZOLES - The present invention relates to crystal forms of 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide and methods for preparation, interconversion, and isolation of such crystals. | 2010-04-15 |
20100093821 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases - The invention relates to novel heterocyclic compounds of the formula | 2010-04-15 |
20100093822 | Process for the Sulfinylation of a Pyrazole Derivative - The present invention relates to a process for the sulfinylation of a pyrazole derivative, characterized in that 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile (II) is reacted with a sulfinylating agent S in the presence of at least one amine acid complex wherein the amine(s) are selected from cyclic secondary amines and the acid(s) are selected from sulfonic acid derivatives, and with the addition of a halogenating agent, wherein S is [CF | 2010-04-15 |
20100093823 | STEROIDAL COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF - A method for the identification of compounds) that control melanin synthesis (melanogenesis), and the preparation and use of such compounds, and compositions and formulations thereof to modify (e.g., inhibit) melanin production are disclosed. A representative compound of the invention is defined by formula I: | 2010-04-15 |
20100093824 | METHODS OF TREATING VIRAL INFECTION - The present invention provides methods of treating an RNA viral infection, generally involving administering an agent that reduces the activity of a host cell protein required for maturation of a viral protein, where the emergence of variant virus resistant to the agent is reduced. The present invention further provides combination therapies for viral infection, involving administration of two or more agents that reduce the activity of a host cell protein required for maturation of a viral protein. | 2010-04-15 |
20100093825 | Bicycloester derivative | 2010-04-15 |
20100093826 | ATROPISOMER OF PYRROLE DERIVATIVE - [Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided. | 2010-04-15 |
20100093827 | METHOD FOR TOPICAL TREATMENT OF TAR-RESPONSIVE DERMATOLOGICAL DISORDERS - A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the composition being in liquid form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal. | 2010-04-15 |
20100093828 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - Disclosed are compounds of formula (IA), formula (IV) or formula (V), and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp | 2010-04-15 |
20100093829 | METHODS FOR PREVENTING, POSTPONING OR IMPROVING THE OUTCOME OF SPINAL DEVICE AND FUSION PROCEDURES - Methods for identifying subjects who could benefit therapeutically from administration of a high specificity cytokine inhibitor are provided. Subjects that are identified include those that are eligible, based on pre-determined criteria, for a spinal device or fusion procedure, such as the implantation of a nucleus replacement device, an annular repair device, or a fusion device. Methods of preventing such procedures or improving the outcome of such procedures are also provided, and include administering a TAT to the subject by any route or regimen of administration, including the regimens described herein. | 2010-04-15 |
20100093830 | Modulation of MLCK-L Expression and Uses Thereof - In various aspects and embodiments the invention provides methods and reagents for controlling gene expression, and for treating disorders and diseases. Embodiments provide methods and reagents specifically for the regulation of MLCK expression and for the use thereof in treating disorders and diseases. Various embodiments provide methods and reagents for specifically down regulating the expression of MLCK-L more efficiently than that of MLCK-S, and for the use thereof in treating disorders and diseases. Embodiments provide siNA for the same, particularly siRNAs. Various of the embodiments are useful for the treatment of inflammatory disorders and diseases, including, for one example in this regard, Asthma. | 2010-04-15 |
20100093831 | NUCLEIC ACID COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH - In certain embodiments, this present disclosure provides nucleic acid compounds, compositions, and methods for inhibiting Ephrin B2 or EphB4 expression. In certain embodiments, the present disclosure provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 2010-04-15 |
20100093832 | MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION IN CANCER - Provided herein are methods, compounds, and compositions for reducing expression of an IGF-IR mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions that inhibit expression of IGF-IR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate the tumor or cancer, or a symptom thereof. | 2010-04-15 |
20100093833 | Methods for Inducing Differentiation of Undifferentiated Mammalian Cells Into Osteoblasts - The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts, including bone formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean bone density in a subject. | 2010-04-15 |
20100093834 | MANIPULATION OF NEURONAL ION CHANNELS - The present invention provides compositions and methods for the manipulation of ion channels. For example, the present invention relates to Parkinson's and other neurological diseases and conditions, and treatments thereof. In particular, the present invention provides methods of decreasing pathophysiological high frequency neuronal bursts of Parkinson's and other neurological diseases and conditions. Methods of the present invention comprise decreasing Kv3 ion channel activity in fast-spiking neurons, including by decreasing activity of a Kv3.4 protein and by specifically targeting a Kv3.4 protein with an inhibitor. | 2010-04-15 |
20100093835 | RNA INTERFERENCE MEDIATED INHIBITION OF MYC AND/OR MYB GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating Myc and/or Myb gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Myc and/or Myb gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of Myc and/or Myb (e.g., c-Myc, N-Myc, L-Myc, c-Myb, a-Myb, b-Myb, and v-Myb) genes. The small nucleic acid molecules are useful in the treatment of cancer and other diseases and disorders. | 2010-04-15 |
20100093836 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN EXPRESSION - The present invention includes compositions and methods useful for modulating protein expression. In certain embodiments, the present invention includes oligomeric compounds comprising modified nucleosides and modified internucleoside linkages. | 2010-04-15 |
20100093837 | MICRORNA MOLECULES | 2010-04-15 |
20100093838 | REGULATION OF ANGIOGENESIS WITH ZINC FINGER PROTEINS - Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided. | 2010-04-15 |
20100093839 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1alpha EXPRESSION - Oligonucleotides directed against the hypoxia-inducible factor-1α (HIP-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof. | 2010-04-15 |
20100093840 | Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy - A method and pharmaceutical compositions useful for inhibiting the growth of solid tumors are provided. Specifically, the method is effected by administering to a subject in need thereof an agent capable of upregulating the expression level and/or activity of at least a functional portion of Sef, wherein the functional portion being capable of inhibiting RTK-mediated cell proliferation. Also provided are methods and kits for diagnosing and staging of cancer by detecting the expression level of hSef in a tissue sample, wherein a decrease in hSef expression level is indicative of cancer. | 2010-04-15 |
20100093841 | CELL CULTURE SYSTEM OF A HEPATITIS C GENOTYPE 3A AND 2A CHIMERA - The present inventors have developed a culture system for genotype 3a, which has a high prevalence worldwide. Since intergenotypic recombinant genomes exploiting the replication characteristics of JFH1 will be a valuable tool for the genotype specific study of the replaced genes and related therapeutics, the present inventors constructed a genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7 and NS2 of strain S52 and characterized it in Huh7.5 cells. S52/JFH1 and J6/JFH viruses passaged in cell culture had comparable growth kinetics and yielded similar peak HCV RNA titers and infectivity titers. Direct genome sequencing of cell culture derived S52/JFH1 viruses identified putative adaptive mutations in Core, E2, p7, NS3 and NS5A; clonal analysis revealed, that all genomes analyzed exhibited different combinations of these mutations. Finally, viruses resulting from transfection with RNA transcripts of five S52/JFH1 recombinant containing these combinations of putative adaptive mutations performed as efficiently as J6/JFH viruses in Huh7.5 15 cells and were all genetically stable after viral passage. In conclusion, the present inventors have developed a robust and genetically stable cell culture system for HCV genotype 3a. | 2010-04-15 |
20100093842 | Laulimalide Analogs and Uses Thereof - The present invention provides compounds having formula I: | 2010-04-15 |
20100093843 | NOVEL NUTRACEUTICAL AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF CARTILAGE DEGRADATION OR CARTILAGE DAMAGE IN JOINTS - The invention relates to novel nutraceutical and pharmaceutical compositions comprising at least a compound of the general formula (I), wherein R | 2010-04-15 |
20100093844 | ORAL COMPOSITION FOR ENHANCING SKIN PROPERTIES - A stable consumable emulsion, comprising at least 50% water, 0.2 to 3 wt % of an oil comprising at least 12 wt % of docosahexaenoic acid and eicosapentaenoic acid, an antioxidant, a flavouring and at least 0.01 wt % food-grade phospholipid emulsifier is provided which provides noticeable improvements in skin when consumed regularly. | 2010-04-15 |
20100093845 | COMPOSITION AND METHOD FOR TREATING DRY EYE SYNDROME - The present invention provides for compositions, medicaments, and methods for treating or alleviating the symptoms of dry eye syndrome or chronic dry eye. More specifically, the present embodiments provide for medicaments consisting of tocopherol or tocotrienol eyedrops. A single topical administration of tocopherol or tocotrienol eyedrops in the eyes of a subject suffering from dry eye alleviates symptoms for at least one day. In particular, the eyedrop medicament consists of α-tocopheryl acetate; α-tocopheryl acetate and about 0.5% aqueous component; or α-tocopheryl acetate, about 2.5% tocopherol emulsifier, and about 20% to about 30% aqueous excipient. | 2010-04-15 |
20100093846 | HYDROXAMATE COMPOSITIONS - The present disclosure provides compositions including a first component including at least one phospholipid possessing at least one vinyl group, a second component including a furanone possessing vinyl and/or acrylate groups, and a third component including a hydroxamate. Compositions, medical devices, and coatings including copolymers and blends of the foregoing components are also provided. | 2010-04-15 |
20100093847 | ANTI-OBESITY ACTIVE AGENT AND ANTI-OBESITY METHOD - [Problem] Fucoxanthin extracted from wakame seaweed ( | 2010-04-15 |
20100093848 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF - A method for treating an individual who has been identified as having Alzheimer's disease by administering orally to the individual a therapeutically effective amount of ladostigil or a pharmaceutically active salt thereof, wherein the therapeutically effective amount is 70 mg per day, 140 mg per day, or 200 mg per day. Also, a unit dosage form of ladostigil or a pharmaceutically active salt thereof in an amount of 50 mg, 70 mg, 80 mg or 100 mg. | 2010-04-15 |
20100093849 | OXALIPLATIN PHARMACEUTICAL COMPOSITION WITH ALCOHOLIC SUGAR-BASED BUFFER - A pharmaceutical composition, intended particularly for potential administration and for treatment of tumor diseases sensitive to oxaliplatinum, comprises oxaliplatinum as the active compound, a pharmaceutically acceptable aqueous solvent and a stabilizing agent in stabilizingly effective amount. The stabilizing agent includes at least one compound selected from the group consisting of acids derived from neutral alcoholic sugars, lactones of these acids and salts of these acids. In a method of producing such a pharmaceutical composition, oxaliplatinum is dissolved in an aqueous solvent, whereupon to the obtained oxaliplatinum solution is added at least one acid derived from a neutral alcoholic sugar and/or at least one lactone of these acids and/or at least one salt of these acids, and optionally the pH value of the solution is adjusted by addition of an alkali metal hydroxide and/or an alkali earth metal hydroxide to pH 3.5-6.5, whereupon the obtained solution is sterilized and filled into individual package units and optionally inertized with nitrogen or argon. | 2010-04-15 |
20100093850 | COMPOSITION CONTAINING METAL-ACIDIC AMINO ACID CHELATE ACCELERATING ABSORPTION OF METAL - Provided is a composition for accelerating absorption of metals, comprising a metal-acidic amino acid chelate as an active ingredient. The composition of the present invention has therapeutic effects on prevention and treatment of various diseases arising from a deficiency or shortage of metals, by utilization of a metal-acidic amino acid chelate that exhibits excellent effects of improving delivery and absorption of a drug into target organs, such that pharmaceutical effects of individual metals can be exerted. In particular, a pharmaceutical composition comprising a zinc-aspartate chelate increasing an intraprostatic zinc content as an active ingredient is highly effective for prevention and treatment of prostate and testicular diseases. | 2010-04-15 |
20100093851 | SILVER POLYAMIDE COMPOSITE - A polymer composite comprising a thermoplastic polyamide polymer compounded with an organo-disulfide additive and a silver-based antimicrobial agent is disclosed. The organo-disulfide additive inhibits undesirable discoloration of the thermoplastic polyamide polymer including one or more silver-based antimicrobial agent. Processes for preparing the composite are also disclosed, including compounding the organo-disulfide additive in a polymeric carrier with the silver-based antimicrobial agent, then with the thermoplastic polyamide polymer, or compounding the organo-disulfide additive with the thermoplastic polyamide polymer before adding the silver-based antimicrobial agent. | 2010-04-15 |
20100093853 | USE OF (-)(3-TRIHALOMETHYLPHENOXY)(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERLIPIDEMIA - The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia. | 2010-04-15 |
20100093854 | PROCESS FOR THE PREPARATION OF (-)-(4-CHLORO-PHENYL)-(3-TRIFLUOROMETHYL-PHENOXY)-ACETIC ACID 2-ACETYLAMINO-ETHYL ESTER - The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid, a synthesis intermediate. | 2010-04-15 |
20100093855 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA - The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. | 2010-04-15 |
20100093856 | OMEGA-3 DIGLYCERIDE EMULSIONS - The present invention relates to omega- | 2010-04-15 |
20100093857 | AMIDO-AMINE POLYMER COMPOSITIONS - Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans. | 2010-04-15 |
20100093858 | USE OF L-CARNITINE OR OF ALKANOYL L-CARNITINES FOR THE PREPARATION OF A PHYSIOLOGICAL SUPPLEMENT OR MEDICAMENT FOR OPHTHALMIC USE IN THE FORM OF EYE DROPS - Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an opthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases. | 2010-04-15 |
20100093859 | Compositions and Methods For Enhancing Neurological Development - Compositions and methods useful to enhance neurologic development of a growing animal are disclosed. | 2010-04-15 |
20100093860 | HYDROXYBUTYRATE AND POLY-HYDROXYBUTYRATE AS COMPONENTS OF ANIMAL FEED OR FEED ADDITIVES - This invention relates to the use of hydroxybutyrate and poly hydroxybutyrate as components of animal feed or feed additives, as well as to compositions, feed additives and feed containing them. The inventors surprisingly found that hydroxybutyrate and poly-hydroxybutyrate, preferably 3-hydroxybutyrate and poly-3-hydroxybutyrate, have a great potential for use in animal feed for modulation of the gut flora. More precisely, it has been found that poly-3-hydroxybutyrate or a microbial strain capable for producing poly-3-hydroxybutyrate can be used as a potential growth promoter or gut flora modulator by releasing SCFA, preferably 3-hydroxy butyric acid, in the gut micro flora. Further, the inventors found that 3-hydroxybutyrate and poly-3-hydroxybutyrate have a great potential for suppressing or inhibiting pathogenic bacteria in the gastro intestinal tract, e.g. have a antimicrobial activity against strains of | 2010-04-15 |
20100093861 | TREATMENT OF INSULIN RESISTANCE OR DISEASES ASSOCIATED WITH INSULIN RESISTANCE - The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a composition for the treatment of insulin resistance or diseases associated with insulin resistance, preferably in human subject in a daily dosage in a range of from about 5 mg to about 1500 mg. The invention furthermore relates to a method of treating insulin resistance or diseases associated with insulin resistance in a mammal, said method comprises administering to said mamma, preferably a human subject, a substance with the core structure of formula (I), preferably in a daily dosage in a range from about 5 mg to about 1500 mg. The substance is preferably isosteviol or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. Examples of diseases associated with insulin resistance are e.g. type 2 diabetes mellitus, insulin resistance syndrome, impaired glucose tolerance, the metabolic syndrome, hyperglycemia, hyperinsulinemia, arteriosclerosis, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, dyslipidemia, obesity, central obesity, polycystic ovarian syndrome, hypercoagulability, hypertension, microalbuminuria, or any combinations thereof. | 2010-04-15 |
20100093862 | POTENTIATION OF CELLULAR IMMUNITY USING HISTONE DEACETYLASE (HDAC) INHIBITORS. - [Technical Problem] The present invention provides an enhancer of cellular immunity, and provides applications to carcinogenesis or preventive therapy against cancer recurrence, immunotherapy for cancer, treatment for pathogenic microorganism infection, and the like. | 2010-04-15 |
20100093863 | USE OF CITRULLINE FOR PREVENTING AN INCREASE IN PROTEIN CARBONYLATION AND FOR TREATING DISEASES RESULTING THEREFROM - A method of using L-citrulline of the formula (I) for preparing a cosmetic composition, a food or nutraceutic composition or a pharmaceutical composition for treating diseases related to an increase in protein carbonylation, in particular for treating neurodegenerative diseases such as Alzheimer's or Parkinson's disease. | 2010-04-15 |
20100093864 | ANTI-INFECTIVE THIOUREA COMPOUNDS - The present application discloses thiourea compounds for use in the treatment of infections. The thiourea compounds have formula (I) wherein X | 2010-04-15 |
20100093865 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - Provided are sulphur-linked compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions. | 2010-04-15 |
20100093866 | Pharmaceutical Formulations - The invention relates to the use of magnesium stearate to inhibit or reduce chemical degradation of an active ingredient substance in a formulation comprising a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical degradation. | 2010-04-15 |
20100093867 | Method Of Treating Genetic Disease Caused By Nonsense Mutation - An object of the present invention is to provide compounds having read-through activity for use in treatment methods of genetic diseases caused by nonsense mutation, to provide pharmaceutical compositions comprising the compound, and to provide a treatment method of genetic diseases caused by nonsense mutation comprising administering the compound. | 2010-04-15 |
20100093868 | WATER-SOLUBLE METAL-PROCESSING AGENT, COOLANT, METHOD FOR PREPARATION OF THE COOLANT, METHOD FOR PREVENTION OF MICROBIAL DETERIORATION OF WATER-SOLUBLE METAL-PROCESSING AGENT, AND METAL PROCESSING - Disclosed are a water-soluble metal-processing agent and a coolant both of which have excellent microbial deterioration resistance and are less likely to go rotten, a method for preparing the agent or the coolant, and a metal processing method. The water-soluble metal-processing agent or the coolant comprises an N,N,N′,N′-tetraalkyldiamine compound. The metal processing method is characterized by processing a metal of interest by using the water-soluble metal-processing agent or the coolant. | 2010-04-15 |
20100093869 | SENSATION MASKING COMPOSITION - The present invention provides masking compositions that include a lower alkyl carboxylic acid, e.g. acetic acid. Also provided is a masking composition that includes (a) a lower alkyl carboxylic acid (e.g. acetic acid), a warming sensate (e.g. vanillin or vanillyl butyl ether) and/or a cooling sensate (e.g. menthol or isopulegol). | 2010-04-15 |
20100093870 | HERBAL MEDICAMENTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS - The present invention relates to A composition obtained from the lipid soluble extract of rhizomes and leaves of | 2010-04-15 |
20100093871 | AGENT FOR PREVENTION OR TREATMENT OF IRON OVERLOAD DISORDERS - Disclosed is an agent for prevention or treatment of iron overload disorders, comprising 22β-methoxyolean-12-ene-3β,24(4β)-diol or a pharmacologically acceptable salt thereof. | 2010-04-15 |
20100093872 | STABLE AQUEOUS FORMULATIONS OF WATER INSOLUBLE OR POORLY SOLUBLE DRUGS - A novel pharmaceutical formulation and process for manufacturing an aqueous based formulation of drugs with low or no water solubility. The drug is combined with the inclusion carrier cyclodextrin, eliminating the need for using organic solvents, to combine the drug, in an aqueous solution of cyclodextrin and heating the resulting mixture above its melting point and allowing the drug to be drawn into the cyclodextrin. | 2010-04-15 |
20100093873 | Methods of improving therapy of perfluorocarbons (PFC) - This invention describes a novel, two-step method for administering PFC. The first step is designed to block the RES by administration of empty, small, liposomal vesicles (ESV) that are rapidly and preferentially engulfed by macrophages, thereby inhibiting their phagocytosis of subsequently infused PFC emulsions. The second step is the subsequent injection of PFC. ESV are devoid of materials that interfere with the macrophage's metabolic processes and do not impair their ability to clear the circulation of pathogenic organisms. Inhibition of the removal of PFC from the blood stream by the RES will achieve increased circulating PFC, enhanced binding and transport of oxygen throughout the blood stream and consequential reduction of undesirable consequences such as organomegaly and cytokine toxicity. | 2010-04-15 |
20100093874 | COPOLYMER INCLUDING BETAINE UNITS AND HYDROPHOBIC AND/OR AMPHIPHILIC UNITS, METHOD FOR PREPARING SAME AND USES THEREOF - The invention relates to a copolymer including betaininc units and hydrophobic and/or amphiphile units. The invention also relates to a method for preparing a copolymer including betaininc units and hydrophobic and/or amphiphile units, by controlled micellar polymerisation. The invention further relates to the uses of the copolymer. The copolymer is particularly used for increasing the viscosity of saline aqueous compositions. | 2010-04-15 |
20100093875 | GRANULAR PREPARATION PREVENTED FROM CAKING - The present invention provides a granular preparation that resists caking during preservation, namely, a granular preparation characteristically with suppressed caking, which comprises an active ingredient other than biguanide, a sugar or a sugar alcohol, an organic acid and a particular water-soluble polysaccharide; and a method of suppressing caking of a granular preparation, which includes adding a particular water-soluble polysaccharide to the active ingredient, sugar or sugar alcohol and organic acid. | 2010-04-15 |
20100093876 | FISCHER-TROPSCH CATALYST - A composition for use as a catalyst or catalyst precursor for the conversion of synthesis gas to hydrocarbons said composition comprises (i) cobalt either as the elemental metal, oxide or a compound thermally decomposable to the elemental metal or oxide and (ii) zinc in the form of the oxide or a compound thermally decomposable to the oxide and (iii) platinum in elemental form or in the form of a compound characterised in that the platinum metal is present in the composition in amount in the range 0.0001 to 1.50% w/w. The compositions show improved activity over a wide temperature range than prior art compositions and also exhibit improved methane selectivity. | 2010-04-15 |
20100093877 | Pillow panel reactor and process - A novel catalytic reactor suitable for use in chemical and petrochemical processes. The reactor is of a pillow panel that has superior heat transfer properties. This invention also relates to a chemical process, such as a Fischer-Tropsch synthesis process performed with use of the novel pillow panel reactor. | 2010-04-15 |
20100093878 | CROSSLINKABLE FLUOROPOLYMER, CROSSLINKED FLUOROPOLYMERS AND CROSSLINKED FLUOROPOLYMER MEMBRANES - Crosslinkable fluoropolymers and crosslinked fluoropolymers prepared from select fluorinated monomers by dimerization and trimerization. Also disclosed are proton conductive membranes of these crosslinked fluoropolymers. | 2010-04-15 |
20100093879 | High Selectivity Polymer-Nano-Porous Particle Membrane Structures - Methods comprising mixing at least one nano-porous particle into a homogeneous solution of a polymer and a diluent at an elevated temperature to form a mixture; and cooling the mixture to solidify the polymer. Membranes comprising at least one nano-porous particle; and a polymer; wherein the at least one nano-porous particle comprises pores ranging from about 0.1 nanometers to about 10,000 nanometers in size. | 2010-04-15 |
20100093880 | RECYCLING CLEAVAGE OF POLYURETHANES - A process is described for splitting polyurethanes and polyurethaneureas, in which the polymer is first reacted with gaseous or liquid secondary aliphatic or cycloaliphatic amines, the secondary urea formed, after removal with hydrogen chloride, is split to the isocyanate, and the polyols or polyamines also formed in the reaction are worked up and purified. It is possible by the process according to the invention to work up polyurethanes, polyurethaneureas, etc., of any origin, and to break them down into the starting materials, specifically the isocyanates, polyols or polyamines, to form starting materials in very high quality, which can be reused for the synthesis of any polyurethanes or polyureas. The invention further provides for the preparation of secondary bis-ureas from polyurethanes or polyurethaneureas or/and ureas. | 2010-04-15 |
20100093881 | PROCESS FOR PRODUCING WOOD/PLASTIC COMPOSITES AND FOAMS USING FOAMING AGENTS CONTAINING ZEOLITE, AND WOOD/PLASTIC COMPOSITES AND FOAMS PRODUCED THEREBY - The present invention relates to cellulosic material/polymer composites and foams containing zeolite, blowing agent(s) and masterbatch(es) for making such composites and foams, and processes therefor. More specifically, in the embodiments of the present invention directed to cellulosic material/polymer foams, the compositions comprise one or more zeolites and one or more foaming agents, wherein the foaming agent(s) preferably is carried by the zeolite(s) and evolves to form foamed products when processed with foamable materials. The present invention also comprises blowing agent composition(s) comprised of zeolite(s) and foaming agent(s) combination(s), and masterbatch composition(s) comprised of zeolite(s), foaming agent(s) and cellulosic material(s). The zeolite provides several benefits to such compositions and foams. The zeolites also have been found to reduce the tendency of the wood portion of the compositions and foams to discolor and have biocidal activity which reduces the tendency of the compositions and foams to degrade from bacterial and fungal attack. | 2010-04-15 |
20100093882 | FLAME RETARDANT AQUEOUS LIQUID COMPOSITION, USE THEREOF FOR PRODUCING FLAME RETARDANT POLYURETHANE FOAM, AND FLAME RETARDANT POLYURETHANE FOAM ARTICLE - A flame retardant aqueous liquid composition containing water, guanidine sulfamate, a citric acid compound including a metal salt of citric acid, and a water soluble polymer. A flame retardant polyurethane foam is produced by a process including the steps of providing a mixture of the above flame retardant aqueous liquid composition with a polyol and an isocyanate, and reacting the mixture in the presence of a catalyst. | 2010-04-15 |
20100093883 | Hydroxamic Esters as Photoinitiators - The present invention concerns photopolymerisable systems comprising reactive oligomers and/or monomers having ethylenically unsaturated groups and as photoinitiator at least one hydroxamic ester of Formula (I) or (II) or (III). | 2010-04-15 |
20100093884 | RADIATION-CURABLE FORMULATIONS COMPRISING SILICA AND DISPERSANT AND FEATURING ENHANCED CORROSION CONTROL ON METAL SUBSTRATES - The invention relates to silica-containing radiation-curable formulations which in the cured state offer a particular degree of corrosion control for metallic substrates. | 2010-04-15 |
20100093885 | PLASTICIZER PREPARATIONS - The present invention relates to plasticizer preparations based on triacetin with short gel time, and to their use, and to polyvinyl chloride preparations. | 2010-04-15 |
20100093886 | ORGANIC AND INORGANIC COMPOSITE FILLER - To provide an organic and inorganic composite filler which gives excellent surface smoothness similar to that of a natural tooth, low polymerization shrinkage, high X-ray imaging property and high mechanical strength to a dental restoration material composite, an organic and inorganic composite filler used for a dental restoration material is produced by curing and pulverizing a (meth)acrylate compound including 50 to 80% by weight of a glass powder having a maximum particle diameter of 5 μm or less, an average particle diameter from 0.05 to 2 μm, and X-ray imaging property, and 10 to 40% by weight of a metal compound having an average particle diameter from 0.005 to 0.3 μm and X-ray imaging property at the maximum of 90% by weight in total, where the organic and inorganic composite filler has preferably an average particle diameter from 10 to 30 μm. | 2010-04-15 |
20100093887 | STAINS, COATINGS AND SEALERS - A composition for treating wood, concrete, and related materials to effect sealing the article against water, preventing microbial attack, protecting against UV degradation, and optionally imparting a color for aesthetic purposes and an article treated with the composition. The composition includes a solvent having an elevated flash point, no VOC's or substantially no VOC's, facilitating its use inside with little or no additional ventilation. The compositions contain no antioxidants, or low and controlled levels of antioxidants to allow the applied composition to properly oxidize and cure upon exposure to air. The compositions can be applied by all conventional methods known for applying sealants and stains. | 2010-04-15 |
20100093888 | POLYLACTIC ACID COMPOSITION - It is an object of the present invention to provide a polylactic acid composition having excellent crystallinity, wet heat stability and melt stability. It is another object of the present invention to provide a molded article which is obtained from the polylactic acid composition and excellent in appearance and color. The present invention is a composition and molded article thereof which comprises a polylactic acid (component A), a carbodiimide compound (component B) and a phosphoric acid ester metal salt (component C). | 2010-04-15 |
20100093889 | POLYLACTIC ACID COMPOSITION - An object of the present invention is to provide a composition containing polylactic acid and having improved blow moldability and a blow molded product thereof. | 2010-04-15 |
20100093890 | BIODEGRADABLE RESIN COMPOSITION AND METHOD FOR PRODUCING THE SAME - The present invention relates to a biodegradable resin composition containing a resin component comprising polylactic acid and polybutylene terephthalate, and a powdered vegetable fiber component comprising corn starch, and relates to a method for producing the same. The present biodegradable resin composition contains the resin component (A) comprising 20 to 50 parts by weight of polylactic acid and 10 to 40 parts by weight of polybutylene terephthalate, and the powdered vegetable fiber component (B) comprising 10 to 70 parts by weight of corn starch, the total of the resin component (A) and the powdered vegetable fiber component (B) amounting to 100 parts by weight. The present biodegradable resin composition can be suitably used for producing a molded article. | 2010-04-15 |
20100093891 | Self-Viscosifying and Self-Breaking Gels - The invention provides a method. The method injects into a wellbore, a fluid comprising at least one of an acrylamide polymer and an acrylamide copolymer, and at least one of an oxidizing agent and a radical initiator; and allows viscosity of the fluid to increase for a first period of time; and subsequently, allows viscosity of the fluid to decrease for a second period of time. In a further aspect the invention provides a fluid for use in a well within a subterranean formation penetrated by a wellbore. The fluid is in a first embodiment, made of an acrylamide polymer and/or copolymer and an oxidizing agent or radical initiator, wherein concentration of the oxidizing agent or radical initiator is such that the fluid increases its viscosity for a period of time and after said period of time decreases its viscosity. The fluid is in a second embodiment, made of an acrylamide polymer and/or copolymer and an oxidizing agent or radical initiator, wherein the oxidizing agent or radical initiator is such that the fluid increases its viscosity for a period of time and after said period of time decreases its viscosity. | 2010-04-15 |
20100093892 | FLUORORUBBER COMPOSITION, CURED FLUORORUBBER FORMED ARTICLE USING THE SAME AND METHOD FOR PRODUCING THEREOF - There are provided a polyol curable fluororubber composition using a fluororubber of general use, a cured fluororubber formed article used as a grommet, a seal packing and the like for a gas sensor which can be used under high temperature circumstances using this, and a method of producing the same. A polyol curable fluororubber composition, which comprises 100 parts by weight of a fluororubber, 6 to 15 parts by weight of magnesium oxide, 0.5 to 5 parts by weight of a hydrotalcite group compound and 20 to 55 parts by weight of a mixture of thermal black and a bituminous coal filler. A cured fluororubber formed article which is produced by forming and curing the fluororubber composition in the presence of a polyol curing agent, and then subjecting the cured formed product to a stepwise temperature elevation treatment in a temperature range of 100° C. to 300° C. According to the present invention, an article which can be used as a grommet, seal packing and the like for a gas sensor under high temperature circumstances, such as an oxygen sensor for an automobile, can be produced, at a reduced cost. | 2010-04-15 |
20100093893 | Removing Fluorosurfactant from Aqueous Fluoropolymer Dispersions Using Anion Exchange Polymer With Functional Groups Resistant To Degradation to Trialkylamines - A process for reducing fluorosurfactant content of a stabilized fluorosurfactant-containing aqueous fluoropolymer dispersion comprising contacting the stabilized fluorosurfactant-containing aqueous fluoropolymer dispersion with an anion exchange resin comprising a polymer and quaternary ammonium functional groups to reduce fluorosurfactant content, the functional groups being resistant to degradation which releases trialkylamines. The anion exchange resin is separated from the dispersion after the fluorosurfactant content has been reduced. | 2010-04-15 |
20100093894 | Removing Fluorosurfactant From Aqueous Fluoropolymer Dispersions Using Anion Exchange Polymer with Functional Groups Resistant to Degradation to Trialkyl Amines - A process for reducing fluorosurfactant content of a stabilized fluorosurfactant-containing aqueous fluoropolymer dispersion comprising contacting the stabilized fluorosurfactant-containing aqueous fluoropolymer dispersion with an anion exchange resin comprising a polymer and quaternary ammonium functional groups to reduce fluorosurfactant content, the functional groups being resistant to degradation which releases trialkylamines. The anion exchange resin is separated from the dispersion after the fluorosurfactant content has been reduced. | 2010-04-15 |
20100093895 | Process for producing polymers having amide and ester groups in the solid state - The present invention relates to a process for the preparation of a polymer P having amide and ester groups in the solid state of aggregation, in a first step (a) a homo- or copolymer P1 of (meth)acrylic acid, itaconic acid or crotonic acid being reacted with at least one monohydroxy compound E at a temperature up to 200° C. to give a polymer P2, so that anhydride groups form in addition to ester groups, in a second step (b) the polymer P2 prepared in step (a) being cooled to below 60° C. so that the polymer P2 is present in the solid state of aggregation or as supercooled melt, and in a third step (c) the polymer P2 having anhydride groups and present in the solid state of aggregation or as supercooled melt being amidated with at least one amine compound A at temperatures below 60° C., the amine compound A used in the third step (c) being present in the solid state of aggregation or on or in a solid carrier material. | 2010-04-15 |
20100093896 | Protein/Cationic Polymer Compositions Having Reduced Viscosity - The present invention discloses an adhesive composition comprising a protein component, an azetidinium functionalized polymer component and a viscosity modifying component. The preferred protein is a soy protein and the viscosity modifying component is preferably a sulfite reducing agent, a thiol, or combinations thereof. The invention provides for a high solids, lower viscosity adhesive formulation. The present invention also relates to a composite and a method of making a composite comprising a substrate and the adhesive composition of the present invention. | 2010-04-15 |
20100093897 | COMPOSITION AND METHOD FOR INHIBITING POLYMERIZATION AND POLYMER GROWTH - A method for inhibiting the premature polymerization and the polymer growth of ethylenically unsaturated monomers is disclosed wherein the method comprises adding to said monomers an effective amount of at least one hydrogen donor or electron acceptor. In a preferred embodiment, the hydrogen donor or electron acceptor is used in combination with a stable nitroxyl free radical. | 2010-04-15 |
20100093898 | Oxygen Plasma-Resistant Composition Characterized By Low Sticking, and Related Methods - The invention provides a curable fluoroelastomeric composition comprising: (i) a fluoropolymer comprising at least one cure site monomer that comprises at least one cyano group; (ii) a cure system comprising a functionalized biphenyl-based compound and at least one of: a dioxime compound represented by the formula (I): HON═R | 2010-04-15 |
20100093899 | RESIN ADDITIVE MASTER BATCH - The invention provides a resin additive master batch which can contain a resin additive having a melting point of not higher than 80° C. to a high concentration, with which breakage of a strand does not occur and continuous production can be attained, and with which the surface tackiness of pellets is improved. | 2010-04-15 |
20100093900 | WATER-BASED INK-JET RECORDING INK - An ink-jet recording ink which is utilized for printing on a heated recording medium, wherein the ink contains at least (1) a pigment, (2) an ink-soluble resin of 2-10 weight % based on a solid content, (3) a water-soluble organic solvent, and (4) a silicone type or a fluorine type surfactant, and the ink-soluble resin and the water-soluble organic solvent satisfy the following conditions: 1) at least one type of the ink-soluble resin is provided with a carboxyl group as an acid group, and an acid value of not less than 80 and less than 300, and 2) the water-soluble organic solvent contains at least 5-15 weight % of solvent A, and 2-15 weight % of solvent B; solvent A: a glycol ether or 1,2-alkanediols, and solvent B: a cyclic solvent, a cyclic ester solvent or a dimethyl sulfoxide, containing a nitrogen or a sulfur atom. | 2010-04-15 |
20100093901 | POLYACETAL RESIN COMPOSITION AND MOLDED ARTICLE THEREOF - The present invention provides a polyacetal resin composition having excellent processability and stability, significantly suppressing the amount of formaldehyde generated from the molded article thereof, and preventing the bleeding of blending components. Specifically, to 100 parts by weight of (A) a polyacetal copolymer in which the amount of hemiformal terminal group is 1.0 mmol/kg or less, the amount of formyl terminal group is 0.5 mmol/kg or less, and the amount of unstable terminal group is 0.5% by weight or less, there are added: 0.01 to 3 parts by weight of (B) a hindered phenol-based antioxidant; 0.01 to 1 part by weight of (C) a hydrazide compound; and 0.01 to 1 part by weight of a compound selected from (D) an isocyanate compound, an isothiocyanate compound, and a modified compound thereof. | 2010-04-15 |
20100093902 | Blocked-Isocyanate Silicone Resins - This invention relates to new blocked isocyanate silicone resins which can be used to make shelf stable one part curable coating compositions. These coatings do not cure until heated. The coatings provide weather resistant protection for numerous substrates including automobile exteriors, leather fabric, electronic components, wood floors and surfaces. | 2010-04-15 |
20100093903 | SPRAYABLE COMPOSITION - The invention relates to a sprayable composition containing an aqueous pressure-sensitive adhesive component as well as tetrafluoroethane, nitrogen, carbon dioxide, and/or compressed air. A further subject of the invention is an aerosol container, having a closable spray opening, that contains the composition. | 2010-04-15 |